Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
WEBINAR: Best practices in global flow cytometry quality control and harmonization 10 days 21 hours 4 mins 48 secs REGISTER NOW

Key qualities to ensure success when outsourcing immunogenicity assay development

23 Oct 2019
Biomarkers Clinical Diagnostics Immunogenicity

immunogenicity-infographic-viracor

< Back to – In the Zone: Immunogenicity

 

 

 

Top content

  • FDA rejects Moderna’s filing for mRNA-1010 flu vaccine
  • Tears tell a story: detecting diabetic retinopathy early
  • New blood test technology accelerates drug detection in critical situations

Related tags

assay CRO outsourcing Viracor Eurofins
Previous article Next article

Related articles

8 JUN 2011 CHROMATOGRAPHY
High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures
1 SEP 2017 NEWS
Ongoing clinical trial indicates potential for a combined approach in diagnosing cervical cancer
31 MAR 2009 COLLABORATIONS AND MERGERS
Conference Report: Europen Bioanalysis Forum
30 OCT 2014 CLINICAL
Research shows promise for prostate cancer test that utilises long noncoding RNA
18 OCT 2019 CLINICAL
T-cell immunity monitoring and assay development: an interview with Steven Kleiboeker
11 OCT 2019 MS (LC–MS/MS, HRMS, IMS)
Besides quantitative applications what else can hybrid assay technology do that will be important to future biotherapeutic development?
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone